Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: gil bazo i. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
Perez-Gracia JL, Prior C, Guillén-Grima F, Segura V, Gonzalez A, Panizo A, Melero I, Grande-Pulido E, Gurpide A, Gil-Bazo I, Calvo A. Perez-Gracia JL, et al. Br J Cancer. 2009 Dec 1;101(11):1876-83. doi: 10.1038/sj.bjc.6605409. Epub 2009 Nov 10. Br J Cancer. 2009. PMID: 19904265 Free PMC article.
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.
Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I. Ponz-Sarvisé M, et al. Clin Cancer Res. 2011 Jun 15;17(12):4155-66. doi: 10.1158/1078-0432.CCR-10-3381. Epub 2011 May 3. Clin Cancer Res. 2011. PMID: 21540238
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Gil-Bazo I, Arévalo E, Castillo A, Zudaire ME, Carranza OE, Fusco JP, Castañón E, Collado-Gómez V, López I, Gil-Aldea I. Gil-Bazo I, et al. Clin Genitourin Cancer. 2013 Jun;11(2):78-84. doi: 10.1016/j.clgc.2012.11.003. Epub 2012 Dec 21. Clin Genitourin Cancer. 2013. PMID: 23260990
122 results